Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR10624 in severe hypertriglyceridemia
NCT06555640Phase 2Completed
- Sponsor
- Doer Bio
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DR10624 in hypertriglyceridemia (6 cohorts), sponsored by Doer Bio. Primary endpoint: Change of fasting triglyceride at 12 weeks. Started Aug 2024; status: completed.
02
Drugs
DR10624
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT06555640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555640.